Positive Preliminary Results from WEB atai Life Sciences Phase 1b Trial of VLS-01 Buccal Film DMT
atai Life Sciences Announces Positive Phase 1b Trial Results
WEB atai Life Sciences, NASDAQ: ATAI, a global biotechnology company pioneering transformative therapies for mental health, has announced positive preliminary results from its Phase 1b trial of VLS-01, a novel oral formulation of N,N-dimethyltryptamine (DMT).
Encouraging Phase 1b Findings
The Phase 1b study evaluated VLS-01's safety, tolerability, pharmacokinetics (PK), and efficacy in 17 healthy volunteers. The results demonstrated:
- VLS-01 was generally well-tolerated with no drug-related serious adverse events
- Rapid and sustained exposure to DMT was achieved
- VLS-01 showed potential for sustained efficacy over 24 hours
Based on these positive findings, atai plans to initiate a Phase 2a trial comparing VLS-01 to intramuscular DMT in patients with treatment-resistant depression.
Comments